IL-1β/MMP-7 treatment of cystitis:

Claims cover the use of IL-1β inhibitors (such as Anakinra) and/or  MMP-7 inhibitors in the treatment of cystitis.

NKR1 antagonists:

Claims cover the use of NK1R antagonists alone or in combination with Anakinra in the treatment of infections.

IRF7 inhibition:

IRF-7 inhibitors and in particular, siRNA molecules are effective in the treatment of bacterial infections and in particular, kidney infections. Broader claims should be allowed.

Pol II inhibitors:

Claims cover the use of named substances from commensal bacteria to be exploited in immunosuppression as well as in anti-inflammatory and anti-infective therapies.